Welcome to the Investor Relations page. If you are a member of the investment community with a question about Regeneron, please call our Investor Relations Line at (914) 345-7400.
For an e-mail response to your Regeneron investment question, please contact us at invest@regeneron.com.
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has candidates in preclinical programs for other diseases and disorders.
| Recent Events | |
|---|---|
| Jan 13, 2010 |
28th Annual J.P. Morgan Healthcare Conference  View Presentation
|
| Dec 15, 2009 | Deutsche Bank 2009 Biotech Boston Confab Conference |
| Dec 1, 2009 | 21st Annual Piper Jaffray Healthcare Conference |
| Recent Press Releases | |
|---|---|
| Jan 7, 2010 | Regeneron Announces Presentation at the 28th Annual J.P. Morgan Healthcare Conference |
Stock Information
| NASDAQ:REGN
$25.77 + 0.04 |
Feb 8, 2010
4:00 PM ET |
Quotes delay at least 20min., by eSignal.
